Deputy Ministry for Public Health, Ministry of Health, Riyadh, Saudi Arabia.
Infectious Disease Unit, Specialty Internal Medicine, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia; Infectious Disease Division, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA; Infectious Disease Division, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Int J Infect Dis. 2021 Mar;104:452-457. doi: 10.1016/j.ijid.2021.01.028. Epub 2021 Jan 16.
Serologic testing provides better understanding of SARS-CoV-2 prevalence and its transmission. This study was an investigation of the prevalence of antibodies to SARS-CoV-2 among blood donors in Saudi Arabia.
To estimate the seroprevalence of anti-SARS-CoV-2 antibodies among blood donors in Saudi Arabia during the early phase of the COVID-19 pandemic.
Serology results and epidemiological data were analyzed for 837 adult blood donors, with no confirmed SARS-CoV-2 infection, in Saudi Arabia from 20th to 25th May 2020. Seroprevalence was determined using electrochemical immunoassay to detect anti-SARS-CoV-2 antibodies.
The overall seroprevalence of anti-SARS-CoV-2 antibodies was 1.4% (12/837). Non-citizens had higher seroprevalence compared with citizens (OR 13.6, p = 0.001). Secondary education was significantly associated with higher seroprevalence compared with higher education (OR 6.8, p = 0.005). The data showed that the highest seroprevalence was in Makkah (8.1%). Uisng Makkah seroprevalence as the reference, the seroprevalence in other areas was: Madinah 4.1% (OR 0.48, 95% CI 0.12-1.94), Jeddah 2.3% (OR 0.27, 95% CI 0.31-2.25), and Qassim 2.9 % (OR 0.34, 95% CI 0.04-2.89) and these were not statistically different from seroprevalence in the Makkah region.
At the early months of the COVID-19 pandemic in Saudi Arabia, the seroprevalence of antibodies to SARS-CoV-2 among blood donors was low, but was higher among non-citizens. These findings may indicate that non-citizens and less educated individuals may be less attentive to preventive measures. Monitoring seroprevalence trends over time require repeated sampling.
血清学检测可更好地了解 SARS-CoV-2 的流行情况及其传播途径。本研究旨在调查沙特阿拉伯献血者中 SARS-CoV-2 抗体的流行情况。
估计 COVID-19 大流行早期沙特阿拉伯献血者中抗 SARS-CoV-2 抗体的血清阳性率。
分析了 2020 年 5 月 20 日至 25 日沙特阿拉伯 837 名无 SARS-CoV-2 感染确诊的成年献血者的血清学结果和流行病学数据。使用电化学免疫分析法检测抗 SARS-CoV-2 抗体来确定血清阳性率。
抗 SARS-CoV-2 抗体的总血清阳性率为 1.4%(12/837)。与公民相比,非公民的血清阳性率更高(OR 13.6,p = 0.001)。与高等教育相比,中等教育与更高的血清阳性率显著相关(OR 6.8,p = 0.005)。数据显示,麦加的血清阳性率最高(8.1%)。以麦加的血清阳性率为参照,其他地区的血清阳性率分别为:麦地那 4.1%(OR 0.48,95%CI 0.12-1.94)、吉达 2.3%(OR 0.27,95%CI 0.31-2.25)和盖西姆 2.9%(OR 0.34,95%CI 0.04-2.89),与麦加地区的血清阳性率无统计学差异。
在 COVID-19 大流行的早期,沙特阿拉伯献血者中抗 SARS-CoV-2 抗体的血清阳性率较低,但非公民的阳性率较高。这些发现可能表明,非公民和受教育程度较低的个体可能对预防措施不太关注。需要反复抽样来监测血清阳性率随时间的趋势。